Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?

Area of Science:

• Pulmonary Medicine
• Immunology
• Cell Biology

Background:

• Interstitial lung diseases (ILD) involve diffuse lung damage, inflammation, and fibrosis.
• Progressive fibrotic ILDs, like idiopathic pulmonary fibrosis, have high fatality and limited treatments.

Purpose of the Study:

• To review the role of P1 and P2 purinergic receptor signaling in pulmonary fibrosis.
• To discuss potential novel therapeutic strategies targeting purinergic pathways.

Main Methods:

• Literature review of existing data on purinergic signaling in pulmonary fibrosis.
• Analysis of the interplay between inflammation, extracellular nucleotides, and fibrosis progression.

Main Results:

• Extracellular nucleotides activate pro-inflammatory responses via P1 and P2 purinergic receptors.
• These receptors are implicated in tissue fibrosis across organs, including the lungs.
• Purinergic signaling is a key factor in pulmonary fibrosis development and progression.

Conclusions:

• Purinergic signaling plays a complex and pivotal role in pulmonary fibrosis.
• Further research, including human studies, is essential to understand these pathways.
• Targeting P1 and P2 receptors offers potential for new pulmonary fibrosis therapies.